|Table of Contents|

Differential expression of TNF-related apoptosis-inducing ligands and receptors in different thymus tissues and its influence on apoptosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 06
Page:
848-852
Research Field:
Publishing date:

Info

Title:
Differential expression of TNF-related apoptosis-inducing ligands and receptors in different thymus tissues and its influence on apoptosis
Author(s):
Gao Kun; Liang Huagang; Li Jian; Wang Chao
Department of Thoracic Surgery,First Hospital of Qinhuangdao,Shandong Qinhuangdao　066000,China.
Keywords:
thymus tumor; TNF-related apoptosis-inducing ligand; transmembrane receptors; differential expression
PACS:
R736.3
DOI:
10.3969/j.issn.1672-4992.2018.06.008
Abstract:
Objective:To investigate the differential expression of TNF-related apoptosis-inducing ligands and receptors in different thymus tissues,and provide a reference for a role of TRAIL in thymus biology and disease treatment.Methods:6 patients with myasthenia gravis associated with thymic hyperplasia,14 patients with myasthenia gravis associated with thymoma,and 10 normal subjects were selected as the subjects.The differential expression profiles of TNF-related apoptosis-inducing ligands and its transmembrane receptors,nuclear factor-κB activation status,and apoptotic cell counts in normal thymus,thymic hyperplasia and thymoma were investigated.Results:TNF-related apoptosis-inducing ligands and its receptors were expressed in all thymus tissues.The expressions of DR4 and DR5 in thymic hyperplasia were the highest.The active forms of NFκB in all thymus tissues were not detected.Compared with normal thymus,the apoptotic cell counts in thymic hyperplasia and thymoma tissue were higher.Conclusion:The expression levels of TRAIL death receptor(DR4/DR5) among the normal thymus,thymic hyperplasia and thymoma were significantly different.And the TRAIL has important potential value in selective induction of apoptosis in thymus tumor cell.

References:

［1］ Li Y,Chu L,Zhang YF.Advances in immunological mechanism of myasthenia gravis［J］.Chin J Neuroimmunol and Neurol,2015,22(3):209-214.［李媛,楚兰,张艺凡.重症肌无力免疫学机制研究进展［J］.中国神经免疫学和神经病学杂志,2015,22(3):209-214.］
［2］ Breese CR,Adams C,Logel J,et al.Comparison of the regional expression of nicotinic acetylcholine receptor alpha 7 mRNA and［I-125］alpha-bungarotoxin binding in human postmortem brain［J］.Journal of Comparative Neurology,2015,387(3):385-398.
［3］ Pirronti T,Rinaldi P,Batocchi AP,et al.Thymus lesions and myasthenia gravis［J］.Acta Radiologica,2015,43(4):380-384.
［4］ Chen YP,Wang W,Wang ZK,et al.The clinical characteristics of patients with thymoma-associated myasthenia gravis［J］.Chinese Journal of Internal Medicine,2012,51(8):623.
［5］ Okumura M,Inoue M,Kadota Y,et al.Biological implications of thymectomy for myasthenia gravis［J］.Surgery Today,2010,40(2):102-107.
［6］ Nagane M,Huang HJ,Cavenee WK.The potential of TRAIL for cancer chemotherapy［J］.Apoptosis,2001,6(3):191-197.
［7］ Griffith TS,Lynch DH.TRAIL:A molecule with multiple receptors and control mechanisms［J］.Current Opinion in Immunology,1998,10(5):559-563.
［8］ Harith HH,Morris MJ,Kavurma MM.On the TRAIL of obesity and diabetes［J］.Trends in Endocrinology & Metabolism Tem,2013,24(11):578-587.
［9］ Qu JL,Tang B,Liu YP,et al.Role of Cbl family of ubiquitin ligases in TRAIL-induced apoptosis of Jurkat T cells［J］.Chin J Cancer Pre and Tre,2011,18(13):981-984.［曲晶磊,唐冰,刘云鹏,等.泛素连接酶Cbl对TRAIL诱导Jurkat T细胞凋亡调节作用的探讨［J］.中华肿瘤防治杂志,2011,18(13):981-984.］
［10］ Oeckinghaus A,Hayden MS,Ghosh S.Crosstalk in NF-κB signaling pathways［J］.Nature Immunology,2011,12(8):695.
［11］ Liu WB,Men LN,He XT,et al.Clinical analysis on 1 520 patients with myasthenia gravis in southern China［J］.Chin J Neuroimmunol and Neurol,2006,13(6):326-330.［刘卫彬,门丽娜,何雪桃,等.我国南方1520例重症肌无力患者的临床特点［J］.中国神经免疫学和神经病学杂志,2006,13(6):326-330.］
［12］ Lipka AF,Vrinten C,Zwet EWV,et al.Ephedrine treatment for autoimmune myasthenia gravis［J］.Neuromuscular Disorders,2017,27(3):259-265.
［13］ Sophie B,Angela V,Jacqueline P.Myasthenia gravis:A clinical-immunological update［J］.J Neu,2016,263(4):1-9.
［14］ Cretney E,Uldrich AP,Mcnab FW,et al.No requirement for TRAIL in intrathymus negative selection［J］.International Immunology,2008,20(2):267-276.
［15］ Jordan B,Schilling S,Zierz S.Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis［J］.Journal of Neurology,2016,263(1):174.
［16］ Yin W,Giaisi M,Kohler R,et al.Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model［J］.Cancer Letters,2017,389:70-77.
［17］ Dai Yu,Ding Hui,Tian Yuejun,et al.Research progress of TRAIL and urinary tumors［J］.Modern Oncology,2016,24(20):3312-3316.［代宇,丁辉,田跃军,等.TRAIL与泌尿系肿瘤研究进展［J］.现代肿瘤医学,2016,24(20):3312-3316.］
［18］ Sonnemann J,Dreyer L,Hartwig M,et al.Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells［J］.Journal of Cancer Research and Clinical Oncology,2007,133(11):847-858.
［19］ Zhao HT,Wang XK,Xue L.The expression and significance of TRAIL receptor DR4,DR5 mRNA in the oral and maxillofacial dermal hemangioma in infants of different stages［J］.Chinese Journal of Practical Stomatology,2015,8(3):167-169.［赵海涛,王绪凯,薛雷.不同时期婴幼儿口腔颌面部血管瘤TRAIL受体DR4、DR5 mRNA的表达及意义研究［J］.中国实用口腔科杂志,2015,8(3):167-169.］
［20］ Corazza N,Brumatti G,Jakob S,et al.TRAIL and thymocyte apoptosis:Not so deadly［J］?Cell Death & Differentiation,2004,11 Suppl 2(12):S213.
［21］ Liang LM,Wang CZ,Liu SY.Expression and clinical significance of the deathreceptor 5 and decoyreceptor 2 of TNF-related apoptosis-inducing ligand in endometrial cancer［J］.Journal of Bengbu Medical College,2012,37(10):1162-1165.［梁利梅,王才智,刘淑玉.肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义［J］.蚌埠医学院学报,2012,37(10):1162-1165.］
［22］ Wu XB,Cao YL,Xie CW,et al.Expression and significance of TRAIL and its receptors in breast cancer［J］.Cancer Research on Prevention and Treatment,2013,40(4):345-348.［吴晓波,曹亚丽,谢春伟,等.TRAIL及其受体在乳腺癌组织中的表达及意义［J］.肿瘤防治研究,2013,40(4):345-348.］
［23］ Sanlioglu AD,Karacay B,Koksal IT,et al.DcR2(TRAIL-R4) siRNA and adenovirus delivery of TRAIL(Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells［J］.Cancer Gene Therapy,2007,14(12):976

Memo

Memo:
-
Last Update: 2018-01-29